Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $45596 | $24667 | — | — | — | — |
| Enterprise Value | $426470 | $405541 | — | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — |
| P/S Ratio | 7.35 | 3.98 | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 65.39 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | -1.9% | -1.9% | — | — | — | — |
| Operating Margin | -312016.9% | -312016.9% | — | — | — | — |
| Net Profit Margin | -394725.1% | -394725.1% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | — | — | -139.0% | 2.9% | 2.3% | — |
| ROA | -3353.2% | -3353.2% | -124.6% | 2.8% | 2.2% | -8.7% |
| ROIC | — | — | -24.0% | -0.7% | -0.5% | — |
| ROCE | — | — | -34.2% | -0.8% | -0.7% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.00 | 0.00 | — |
| Debt / EBITDA | — | — | — | — | 0.01 | 103.24 |
| Net Debt / Equity | — | — | — | 0.00 | -0.00 | — |
| Net Debt / EBITDA | — | — | — | — | -0.15 | 103.24 |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -2.27 | -2.27 | -13.06 | 498.88 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.17 | 0.17 | 0.09 | 0.20 | 3.62 | 1.00 |
| Quick Ratio | 0.14 | 0.14 | 0.09 | 0.20 | 3.62 | 1.00 |
| Cash Ratio | 0.13 | 0.13 | 0.00 | — | 1.64 | — |
| Asset Turnover | — | 0.00 | — | — | — | — |
| Inventory Turnover | 0.02 | 0.02 | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $1M | $689913 | $479478 | $898437 | $682812 |
Imminent insolvency and dilution
As reported in recent financial statements, ASBPW trades at a price-to-sales ratio of 7.35, a figure that appears disconnected from the company's negligible revenue base and suggests the market is pricing the entity as a speculative IP option rather than a functional operating business.
The P/S multiple is largely meaningless given the lack of commercial scale, as it fails to account for the massive cash burn required to sustain operations. Investors should interpret this valuation as a reflection of potential liquidation value or patent portfolio worth rather than any expectation of near-term earnings growth.
Based on the provided quarterly data, ASBPW's operating margin of -58.1% in 2026Q1 highlights a fundamental inability to cover fixed laboratory overhead, confirming that the company's current unit economics remain deeply negative compared to established biotechnology peers in the molecular diagnostics space.
The extreme volatility in operating margins suggests that the company is struggling to transition from R&D-heavy pilot phases to a repeatable service model. This lack of profitability implies that any future scaling would require a complete overhaul of the current cost structure to achieve positive contribution margins.
According to recent SEC filings, ASBPW's current ratio has deteriorated to 2.26 in 2026Q1, yet this figure masks a precarious cash position of only $1M, which appears insufficient to support the company's ongoing regulatory and operational requirements in the face of persistent, high-burn losses.
The liquidity position is highly vulnerable, as the company lacks the recurring revenue streams necessary to replenish its dwindling cash reserves. Investors should monitor the company's ability to secure external financing, as the current ratio provides a false sense of security given the rapid depletion of liquid assets.
As indicated by the reported inventory days of 1,241 in 2026Q1, ASBPW exhibits significant working capital inefficiency, suggesting that the company is unable to effectively convert its diagnostic assay components into revenue-generating services compared to industry standards for high-throughput laboratory operations.
The extremely high inventory turnover metrics imply that the company is holding stagnant assets that are not contributing to commercial output. This inefficiency warrants further investigation into whether the company's diagnostic platform is technically viable or if it faces structural barriers to market adoption.
Based on the company's unique financial profile, the price-to-earnings ratio is the most commonly misapplied metric, as it obscures the reality that ASBPW is a pre-revenue, distressed entity where earnings are non-existent and traditional valuation multiples fail to capture the underlying insolvency risk.
Analysts should instead focus on cash runway and probability-weighted IP valuation, as these metrics better reflect the company's status as a speculative biotech option. Relying on P/E or other earnings-based ratios in this context may lead to a fundamental misunderstanding of the company's actual financial viability.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ASBPW stock.
Aspire Biopharma Holdings, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, Aspire Biopharma Holdings, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Aspire Biopharma Holdings, Inc. has -1.9% gross margin and -312016.9% operating margin.